New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
11:17 EDTNYMXNymox completes enrollment in U.S. Phase 3 NX02-0017 study of NX-1207
Nymox Pharmaceutical announced completion of patient enrollment in the company's pivotal U.S. Phase 3 NX02-0017 study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3 Study are expected in late 2013. Paul Averback MD, CEO of Nymox said, "Our drug development programs for NX-1207 include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, and other clinical and non-clinical research activities. Over 2000 patients have participated to date in NX-1207 trials. Final completion of enrollment in this major pivotal study is an important milestone in the NX-1207 development pathway. We look forward to further milestones as this and other trials are completed and results are reported."
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:03 EDTNYMXNymox says Phase 2 NX03-0040 study successfully met pre-determined endpoints
Nymox Pharmaceutical Corporation announced results from the completion of the company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate. The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints. "These results demonstrate that a single targeted office injection of fexapotide has led to statistically significant improvement in outcomes with much less surgery or radiotherapy required after 18 months. This means a reduction in patient discomfort, and a reduction in permanent side effects and life changes when the more invasive treatments are required," said Paul Averback, CEO of Nymox.
February 4, 2016
11:19 EDTNYMXNymox announces private placement equity investment of $2.1M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use